1

2
Tarran Jones
Masayuki Tsuchiya, Koh Sato, Mary Margaret Bendig, Steven Tarran Jones, Jose William Saldanha: Reshaped human antibody to human interleukin-6 receptor. Chugai Seiyaku Kabushiki Kaisha, Foley & Lardner, January 20, 2009: US07479543 (80 worldwide citation)

A reshaped human antibody to the human IL-6R, comprising: (A) an L chain comprising, (1) a human L chain C region, and (2) an L chain V region comprising human L chain framework regions (FRs), and mouse L chain complementary determination regions (CDRs) of a momoclonal antibody to the IL-6 receptor ...


3

4
Tarran Jones
Tsuchiya Masayuki, Sato Koh, Bendig Mary Margaret, Jones Steven Tarran, Saldanha Jose William: Reconstituted human antibody against human interleukin 6 receptor.. Chugai Pharmaceutical, December 14, 1994: EP0628639-A1 (47 worldwide citation)

A reconstituted human antibody against a human interleukin 6 receptor (IL-6R), which is composed of: (A) an L chain composed of (1) the C region of a human L chain and (2) the V region of an L chain comprising the framework region (FR) of a human L chain and the complementarity-determining region (C ...


5
Tarran Jones
Gregory J LaRosa, Christopher Horvath, Walter Newman, S Tarran Jones, Siobhan H O&apos Brien, Theresa O&apos Keefe: Humanized anti-CCR2 antibodies and methods of use therefor. Millennium Pharmaceuticals, Hamilton Brook Smith & Reynolds P C, February 24, 2004: US06696550 (36 worldwide citation)

The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the intera ...


6
Tarran Jones
Paul D Ponath, Douglas J Ringler, S Tarran Jones, Walter Newman, José Saldanha, Mary M Bendig: Humanized immunoglobulin reactive with α4β7 integrin. Millennium Pharmaceuticals, Hamilton Brook Smith & Reynolds P C, December 12, 2006: US07147851 (32 worldwide citation)

The present invention relates to humanized immunoglobulins having binding specificity for α4β7 integrin, comprising an antigen binding region of nonhuman origin (e.g., rodent) and at least a portion of an immunoglobulin of human origin (e.g., a human framework region, a human constant region). In on ...


7
Tarran Jones
Mary M Bendig, Olivier J Leger, Jose Saldanha, Tarran S Jones, Ted A Yednock: Methods of inhibiting alpha-4-dependent interactions with VCAM-1 with anti-VLA-4 antibodies. Elan Pharmaceuticals, Crowell & Moring, August 21, 2012: US08246958 (30 worldwide citation)

The invention provides methods of treatment using humanized immunoglobulins that specifically bind to alpha-4 integrin. The methods are useful for treatment of asthma, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, transplant rejection, graft versus host ...


8
Tarran Jones
Gregory J LaRosa, Christopher Horvath, Walter Newman, S Tarran Jones, Siobhan H O&apos Brien, Theresa O&apos Keefe: Recombinant anti-CCR2 antibodies and methods of use therefor. Millennium Pharmaceuticals, Hamilton Brook Smith & Reynolds P C, April 27, 2004: US06727349 (29 worldwide citation)

The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the intera ...


9
Tarran Jones
Robert W Chestnut, Margaret J Polley, James C Paulson, S Tarran Jones, Jose W Saldanha, Mary M Bendig, Michael Kriegler, Carl Perez, Robert Bayer, Michael Nunn: Antibodies to P-selectin and their uses. Cytel Corporation, Campbell & Flores, September 1, 1998: US05800815 (21 worldwide citation)

The present invention relates to compositions and methods for treating inflammation and other pathological conditions using novel blocking P-selectin antibodies that inhibit adhesion of leukocytes to activated platelets and/or to activated vascular endothelium in vivo. Both murine and humanized anti ...


10
Tarran Jones
Britta Hardy, Steven Tarran Jones, Leah Klapper: Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency. CureTech, Mor Research Applications, Winston & Strawn, February 19, 2008: US07332582 (18 worldwide citation)

The present invention provides to a humanized monoclonal antibody having immunostimulatory effects. This antibody binds specifically to B lymphoblastoid cells, induces proliferation and activation of peripheral blood lymphocytes, and is capable of eliciting an anti-tumor effect upon administration t ...



Click the thumbnails below to visualize the patent trend.